News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics Announces Pricing of Initial Public Offering
TUCSON, Ariz. , May 6, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. , a provider of instruments and reagents for molecular profiling applications, today announced the pricing of its initial public offering of 3,570,000 shares of its common stock at an initial public offering price of
View HTML
Toggle Summary HTG Launches a New Highly Multiplexed Profiling Panel Automated on the HTG EdgeSeq System
TUCSON, Ariz., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Today  HTG Molecular Diagnostics , Inc. announced the availability of the HTG EdgeSeq Oncology Biomarker panel for profiling the expression of over 2,500 oncology related biomarkers. Automated on the HTG EdgeSeq system, HTG EdgeSeq Oncology
View HTML
Toggle Summary HTG Announces Completion of IVD Development and Supply Agreement With Illumina
Thursday, October 30, 2014 - 08:08 HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ:ILMN), under which HTG will have the right to develop
View HTML
Toggle Summary HTG Molecular Diagnostics Announces $16 Million Term Loan Agreement With Silicon Valley Bank and Oxford Finance
Tuesday, October 14, 2014 - 08:14 HTG Molecular Diagnostics (“HTG”) today announced that it has closed a growth capital term loan facility with Silicon Valley Bank and Oxford Finance (SVB/Oxford). The loan facility provides HTG with up to $16 million of available proceeds, with $11 million funded
View HTML
Toggle Summary HTG receives US Patent for HTG EdgeSeq chemistry coupling quantitative nuclease protection with next-generation-sequencing
HTG receives US Patent for HTG EdgeSeq chemistry coupling quantitative nuclease protection with next-generation-sequencing TUCSON, AZ--(Marketwired - Jun 17, 2014  ) - HTG Molecular Diagnostics, a provider of instruments and reagents for translational research and molecular diagnostics, today
View HTML
Toggle Summary HTG launches an automated, sequencing-based miRNA Whole Transcriptome digital gene expression assay for challenging sample types
HTG launches an automated, sequencing-based miRNA Whole Transcriptome digital gene expression assay for challenging sample types TUCSON, Ariz. (June 10, 2014) – Today HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of
View HTML
Toggle Summary Patrick Roche, Ph.D., Joins HTG Molecular Diagnostics
TUCSON, Ariz. (April 9, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Patrick Roche, Ph.D., has joined the company as Sr. Vice President for IVD Assay Development. Dr. Roche joins HTG from Ventana Medical Systems/Roche Tissue Diagnostics where he served as Vice President of
View HTML
Toggle Summary HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests
HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests TUCSON, Ariz. (April 7, 2014)  HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene
View HTML
Toggle Summary Lewis Shuster Joins HTG Molecular Diagnostics Board of Directors
Lewis Shuster Joins HTG Molecular Diagnostics Board of Directors TUCSON, Ariz. (March 21, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Lewis (Lew) Shuster has joined its board of directors. Mr. Shuster is CEO of Shuster Capital, a strategic and operating advisory firm to life
View HTML
Toggle Summary HTG Molecular Diagnostics Completes Initial Series E Preferred Stock Offering
TUCSON, Ariz. (February 11, 2014) HTG Molecular Diagnostics (“HTG”) today announced the initial closing of its Series E offering with existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght. Proceeds will support commercial and product development initiatives.
View HTML